Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
https://www.kiniksa.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 297
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Sanj K. Patel | CEO & Chairman of the Board | 1.57M | N/A | 1969 |
Mr. Eben Tessari | Senior VP & COO | 733.29k | N/A | 1982 |
Dr. John F. Paolini FACC, M.D., Ph.D. | Senior VP & Chief Medical Officer | 855.79k | N/A | 1965 |
Mr. Mark Ragosa C.F.A. | Senior VP & CFO | N/A | N/A | 1974 |
Mr. Michael R. Megna CPA | Chief Accounting Officer & Group VP of Finance | N/A | N/A | 1971 |
Ms. Mei Jang | Senior VP of Technical Operations | N/A | N/A | N/A |
Rachel Frank | Associate Director of Investor Relations | N/A | N/A | N/A |
Mr. Chad Morin | Senior VP & Chief Compliance Officer | N/A | N/A | N/A |
Ms. Madelyn Demsky Zeylikman | SVP, General Counsel & Secretary | N/A | N/A | 1974 |
Ms. Melissa Manno | Senior VP & Chief Human Resources Officer | N/A | N/A | N/A |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Kiniksa Pharmaceuticals, Ltd.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 10; Compensation: 8.